S&P 500   0.54 (-1.29%)
DOW   0.54 (-1.29%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   0.54 (-1.29%)
DOW   0.54 (-1.29%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   0.54 (-1.29%)
DOW   0.54 (-1.29%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   0.54 (-1.29%)
DOW   0.54 (-1.29%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
Log in

NASDAQ:KLDOKaleido Biosciences Stock Price, Forecast & News

$6.59
+0.01 (+0.15 %)
(As of 08/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.50
Now: $6.59
$6.75
50-Day Range
$5.97
MA: $6.87
$7.80
52-Week Range
$2.82
Now: $6.59
$10.36
Volume86,009 shs
Average Volume155,906 shs
Market Capitalization$200.95 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.19
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company offers product candidates for the treatment of urea cycle disorders; hepatic encephalopathy; infections caused by multi-drug resistant bacteria; cardiometabolic and liver diseases; and immune oncology. It has a collaboration agreement with Gustave Roussy Cancer Center to develop microbiome metabolic therapies in immuno-oncology; a research collaboration with Washington University School of Medicine to explore the influence of microbiome metabolic therapies on microbial and host physiology and metabolism; and a research collaboration with Janssen to prevent childhood-onset of atopic, immune, and metabolic conditions. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.47 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KLDO
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees91
Market Cap$200.95 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
$6.59
+0.01 (+0.15 %)
(As of 08/6/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KLDO News and Ratings via Email

Sign-up to receive the latest news and ratings for KLDO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Kaleido Biosciences (NASDAQ:KLDO) Frequently Asked Questions

How has Kaleido Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Kaleido Biosciences' stock was trading at $5.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, KLDO shares have increased by 19.0% and is now trading at $6.59.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Kaleido Biosciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Kaleido Biosciences
.

When is Kaleido Biosciences' next earnings date?

Kaleido Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Kaleido Biosciences
.

How were Kaleido Biosciences' earnings last quarter?

Kaleido Biosciences Inc (NASDAQ:KLDO) released its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.59) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.59).
View Kaleido Biosciences' earnings history
.

What price target have analysts set for KLDO?

3 brokerages have issued 1-year target prices for Kaleido Biosciences' shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate Kaleido Biosciences' share price to reach $7.00 in the next twelve months. This suggests a possible upside of 6.2% from the stock's current price.
View analysts' price targets for Kaleido Biosciences
.

Has Kaleido Biosciences been receiving favorable news coverage?

Media stories about KLDO stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Kaleido Biosciences earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about Kaleido Biosciences
.

Are investors shorting Kaleido Biosciences?

Kaleido Biosciences saw a drop in short interest during the month of July. As of July 31st, there was short interest totaling 2,140,000 shares, a drop of 5.7% from the July 15th total of 2,270,000 shares. Based on an average daily volume of 166,900 shares, the days-to-cover ratio is currently 12.8 days. Currently, 19.7% of the company's stock are sold short.
View Kaleido Biosciences' Current Options Chain
.

Who are some of Kaleido Biosciences' key competitors?

What other stocks do shareholders of Kaleido Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Tcr2 Therapeutics (TCRR), Harpoon Therapeutics (HARP), QUALCOMM (QCOM) and Exxon Mobil (XOM).

Who are Kaleido Biosciences' key executives?

Kaleido Biosciences' management team includes the following people:
  • Mr. Michael W. Bonney, Exec. Chair (Age 62, Pay $397.5k)
  • Ms. Alison Lawton, CEO, Pres & Director (Age 59, Pay $1.04M)
  • Dr. Geoffrey von Maltzahn Ph.D., Co-Founder & Director (Age 39, Pay $35k)
  • Mr. Jerald Korn J.D., Gen. Counsel & Corp. Sec. (Age 41, Pay $464.81k)
  • Dr. Katharine Knobil M.D., Chief Medical Officer and Head of R&D (Age 55, Pay $868.03k)

When did Kaleido Biosciences IPO?

(KLDO) raised $101 million in an initial public offering on Thursday, February 28th 2019. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Kaleido Biosciences' stock symbol?

Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO."

Who are Kaleido Biosciences' major shareholders?

Kaleido Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Bessemer Group Inc. (0.12%) and Bainco International Investors (0.05%). Company insiders that own Kaleido Biosciences stock include Kyriazi Theo Melas, Michael W Bonney, Ventures Fund Iv Gene Flagship and Ventures Fund V LP Flagship.
View institutional ownership trends for Kaleido Biosciences
.

Which major investors are selling Kaleido Biosciences stock?

KLDO stock was sold by a variety of institutional investors in the last quarter, including Bainco International Investors.
View insider buying and selling activity for Kaleido Biosciences
.

Which major investors are buying Kaleido Biosciences stock?

KLDO stock was purchased by a variety of institutional investors in the last quarter, including Bessemer Group Inc.. Company insiders that have bought Kaleido Biosciences stock in the last two years include Kyriazi Theo Melas, Michael W Bonney, Ventures Fund Iv Gene Flagship, and Ventures Fund V LP Flagship.
View insider buying and selling activity for Kaleido Biosciences
.

How do I buy shares of Kaleido Biosciences?

Shares of KLDO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kaleido Biosciences' stock price today?

One share of KLDO stock can currently be purchased for approximately $6.59.

How big of a company is Kaleido Biosciences?

Kaleido Biosciences has a market capitalization of $200.95 million. Kaleido Biosciences employs 91 workers across the globe.

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.